**Abstract**

A substantial portion of schizophrenia patients with obsessive compulsive disorder fail to respond to regimen of antipsychotic and selective serotonin reuptake inhibitor. Herein, we report a schizophrenic patient who, after being switched from escitalopram to milnacipran, showed a rapid improvement of his debilitating OCD.

A 23-year-old unemployed single man had been diagnosed with schizophrenia and OCD 4 years previously. A regimen with quetiapine 225 mg/day and escitalopram 20 mg/day has stabilized his psychotic symptoms, however, OCS persisted, with a score of 24 on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). We switched escitalopram to milnacipran at an initial dosage of 100 mg/day, without adding on any psychological or behavioral interventions. By the end of the first week after initiating milnacipran, his Y-BOCS score had dropped to 13. The dose of milnacipran was raised to 150 mg/day at the third week, the patient showed a reduction of about 45% in Y-BOCS score, which is considered to be a significant treatment response.

Milnacipran is a unique SNRI in that it is twice as potent in inhibiting norepinephrine than serotonin reuptake. Among schizophrenic patients, the serotonergic system may receive complex dopaminergic modulations which are further complicated with antipsychotic treatment. In the present case, it is possible that a paradoxical downregulation of serotonergic receptors following his previous antipsychotic treatment may have hindered the therapeutic efficacy of SSRIs in treating OCS. SNRIs with preferential norepinephrine reuptake inhibition, such as milnacipran, may exert a superior efficacy by acting primarily on the noradrenergic circuit. Due to the complex interplay between serotonergic, dopaminergic and noradrenergic systems, the pathogenesis of OCS in patients with schizophrenia may be more complicated than the well-known serotonin hypothesis of OCD. Milnacipran, with its preferable noradrenergic reuptake blockade, can be a reasonable alternative if OCS fail to respond to SSRIs or other SNRIs.
